- Home
- PGEN vs REX Comparison
PGEN vs REX Comparison
Compare PGEN & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | REX |
|---|---|---|
| Founded | 1998 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PGEN | REX |
|---|---|---|
| Price | $4.12 | $51.04 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 146.6K |
| Earning Date | 05-13-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.50 |
| Revenue | $230,981,000.00 | ★ $650,487,000.00 |
| Revenue This Year | $1,115.92 | $19.45 |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | ★ N/A | $19.96 |
| Revenue Growth | N/A | ★ 1.24 |
| 52 Week Low | $1.23 | $30.02 |
| 52 Week High | $5.47 | $64.95 |
Technical Indicators
Market Signals| Indicator | PGEN | REX |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 79.01 |
| Support Level | $3.91 | $49.75 |
| Resistance Level | $4.31 | $55.33 |
| Average True Range (ATR) | 0.19 | 1.33 |
| MACD | 0.00 | 0.40 |
| Stochastic Oscillator | 64.01 | 96.79 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.